- 2008 Annual Report (PDF 469 Kb)
- 2009 - First quarter (PDF 277 Kb)
Ambrilia Biopharma
Ambrilia is a biotechnology company listed on the Toronto Stock Exchange (TSX:AMB) with its head office and R&D and manufacturing facilities located in Montréal Quebec, Canada.
Corporate Strategy
Ambrilia is currently under the protection of the Companies' Creditors Arrangement Act (CCAA).
The company has prioritized the out-licensing and divestment of its product portfolio. The aim of this strategy is to generate non-dilutive R&D funding for Ambrilia and to preserve the companies cash flow.
Ambrilia's product portfolio includes: a sustained release octreotide formulation, a sustained release goserelin formulation, HIV protease inhibitors, HIV integrase and entry inhibitors, HCV entry and polymerase inhibitors and anti-iInfluenza A peptides.
The company has elected to prioritize the divestment of its oncology assets and has put a hold on antiviral R&D activities.

